Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Novel drugs targeting hypertension revisited.

Literature DB >> 20844362

Novel drugs targeting hypertension revisited.

George W Booz.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Antihypertensive Agents

Year: 2010 PMID： 20844362 PMCID： PMC2941914 DOI： 10.1097/FJC.0b013e3181f0d63f

Source DB: PubMed Journal: J Cardiovasc Pharmacol ISSN： 0160-2446 Impact factor: 3.105

× No keyword cloud information.

14 in total

Review 1. Antihypertensive drug development: current challenges and future opportunities.

Authors: Peter U Feig; Sophie Roy; Robert J Cody
Journal: J Am Soc Hypertens Date: 2010-05-27

2. Heart disease and stroke statistics--2010 update: a report from the American Heart Association.

Authors: Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Véronique L Roger; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett
Journal: Circulation Date: 2009-12-17 Impact factor: 29.690

Review 3. Improving blood pressure control rates by optimizing combination antihypertensive therapy.

Authors: Benjamin J Epstein
Journal: Expert Opin Pharmacother Date: 2010-08 Impact factor: 3.889

Review 4. Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.

Authors: Fernanda B M Priviero; R Clinton Webb
Journal: J Cardiovasc Pharmacol Date: 2010-09 Impact factor: 3.105

Review 5. Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim.

Authors: ZhiYuan Pan; JingHui Huang; WenYu Cui; ChaoLiang Long; YanFang Zhang; Hai Wang
Journal: J Cardiovasc Pharmacol Date: 2010-09 Impact factor: 3.105

6. Synergistic activation of vascular TRPC6 channel by receptor and mechanical stimulation via phospholipase C/diacylglycerol and phospholipase A2/omega-hydroxylase/20-HETE pathways.

Authors: Ryuji Inoue; Lars J Jensen; Zhong Jian; Juan Shi; Lin Hai; Andrew I Lurie; Freja H Henriksen; Max Salomonsson; Hiromitsu Morita; Yasuhiro Kawarabayashi; Masayuki Mori; Yasuo Mori; Yushi Ito
Journal: Circ Res Date: 2009-05-14 Impact factor: 17.367

7. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats.

Authors: Vera Certíková Chábová; Agnieszka Walkowska; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Petr Kujal; Zdenka Vernerová; Zdena Vanourková; Libor Kopkan; Herbert J Kramer; John R Falck; John D Imig; Bruce D Hammock; Ivana Vanecková; Ludek Cervenka
Journal: Clin Sci (Lond) Date: 2010-02-23 Impact factor: 6.124

Novel drugs targeting hypertension revisited.

Review 1. Antihypertensive drug development: current challenges and future opportunities.

2. Heart disease and stroke statistics--2010 update: a report from the American Heart Association.

Review 3. Improving blood pressure control rates by optimizing combination antihypertensive therapy.

Review 4. Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.

Review 5. Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim.

6. Synergistic activation of vascular TRPC6 channel by receptor and mechanical stimulation via phospholipase C/diacylglycerol and phospholipase A2/omega-hydroxylase/20-HETE pathways.

7. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats.

Review 8. The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophy.

9. Increased TRPC3 expression in vascular endothelium of patients with malignant hypertension.

Review 10. TRP channel and cardiovascular disease.

1. New take on the role of angiotensin II in cardiac hypertrophy and fibrosis.